Helicobacter pylori infection
Conditions
Interventions
Vonoprazan and high-dose amoxicillin dual therapy group:None
Personalized bismuth-based quadruple therapy group:None
Sponsors
Nanjing Medical University First Affiliated Hospital (Jiangsu Provincial People's Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 65 years, inclusive, of either gender. 2.Confirmed Helicobacter pylori infection, as determined by a positive C13-urea breath test (UBT) performed at our outpatient clinic. 3.History of at least one treatment failure with a standard 14-day quadruple therapy for H. pylori eradication. 4.Confirmed resistance to metronidazole, clarithromycin, and levofloxacin, based on an antibiotic susceptibility test (AST) performed on gastric biopsy samples obtained via gastroscopy. 5.Patients who received a salvage/rescue therapy regimen for refractory H. pylori at the Gastroenterology outpatient clinic of our hospital.
Exclusion criteria
Exclusion criteria: 1.Previous use of furazolidone or tetracycline in any prior H. pylori eradication regimen. 2.Negative culture result from the antibiotic susceptibility test, or confirmed resistance to amoxicillin, furazolidone, or tetracycline. 3.Presence of acute upper gastrointestinal bleeding, peptic ulcer, or early/advanced upper gastrointestinal malignancy, as identified by gastroscopy. 4.Patients who are pregnant or lactating. 5.Patients with severe, uncontrolled primary diseases of major organ systems, including but not limited to hepatic, renal, cardiac, cerebral, pulmonary, endocrine, or hematopoietic systems.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The eradication rate of Helicobacter pylori; | — |
Countries
China
Contacts
Public ContactFeng Ye
Nanjing Medical University First Affiliated Hospital (Jiangsu Provincial People's Hospital)
Outcome results
None listed